These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies. Abdel-Wahab O; Klimek VM; Gaskell AA; Viale A; Cheng D; Kim E; Rampal R; Bluth M; Harding JJ; Callahan MK; Merghoub T; Berger MF; Solit DB; Rosen N; Levine RL; Chapman PB Cancer Discov; 2014 May; 4(5):538-45. PubMed ID: 24589925 [TBL] [Abstract][Full Text] [Related]
26. Combining Tumor-Selective Bacterial Therapy with Salmonella typhimurium A1-R and Cancer Metabolism Targeting with Oral Recombinant Methioninase Regressed an Ewing's Sarcoma in a Patient-Derived Orthotopic Xenograft Model. Miyake K; Kiyuna T; Li S; Han Q; Tan Y; Zhao M; Oshiro H; Kawaguchi K; Higuchi T; Zhang Z; Razmjooei S; Barangi M; Wangsiricharoen S; Murakami T; Singh AS; Li Y; Nelson SD; Eilber FC; Bouvet M; Hiroshima Y; Chishima T; Matsuyama R; Singh SR; Endo I; Hoffman RM Chemotherapy; 2018; 63(5):278-283. PubMed ID: 30673664 [TBL] [Abstract][Full Text] [Related]
27. Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison. Atkins MB; Tarhini A; Rael M; Gupte-Singh K; O'Brien E; Ritchings C; Rao S; McDermott DF Immunotherapy; 2019 May; 11(7):617-629. PubMed ID: 30852924 [TBL] [Abstract][Full Text] [Related]
28. Cobimetinib. Signorelli J; Shah Gandhi A Ann Pharmacother; 2017 Feb; 51(2):146-153. PubMed ID: 27701080 [TBL] [Abstract][Full Text] [Related]
29. Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic. Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Miyake M; Li S; Han Q; Tan Y; Zhao M; Li Y; Nelson SD; Dry SM; Singh AS; Elliott IA; Russell TA; Eckardt MA; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Eilber FC; Hoffman RM Cell Cycle; 2018; 17(6):801-809. PubMed ID: 29374999 [TBL] [Abstract][Full Text] [Related]
30. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494 [TBL] [Abstract][Full Text] [Related]
31. BRAF Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031 [TBL] [Abstract][Full Text] [Related]
32. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer. Joshi M; Rice SJ; Liu X; Miller B; Belani CP PLoS One; 2015; 10(2):e0118210. PubMed ID: 25706985 [TBL] [Abstract][Full Text] [Related]
33. Tumor-targeting Salmonella typhimurium A1-R is a highly effective general therapeutic for undifferentiated soft tissue sarcoma patient-derived orthotopic xenograft nude-mouse models. Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Miyake M; Singh AS; Eckardt MA; Nelson SD; Russell TA; Dry SM; Li Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Singh SR; Eilber FC; Hoffman RM Biochem Biophys Res Commun; 2018 Mar; 497(4):1055-1061. PubMed ID: 29481803 [TBL] [Abstract][Full Text] [Related]
34. Tumor-targeting Salmonella typhimurium A1-R in combination with doxorubicin eradicate soft tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) model. Murakami T; DeLong J; Eilber FC; Zhao M; Zhang Y; Zhang N; Singh A; Russell T; Deng S; Reynoso J; Quan C; Hiroshima Y; Matsuyama R; Chishima T; Tanaka K; Bouvet M; Chawla S; Endo I; Hoffman RM Oncotarget; 2016 Mar; 7(11):12783-90. PubMed ID: 26859573 [TBL] [Abstract][Full Text] [Related]